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Dynamic combinatorial chemistry: a tool to facilitate
the identification of inhibitors for protein targets
Milon Mondal and Anna K. H. Hirsch*
Dynamic combinatorial chemistry (DCC) has emerged as a powerful strategy to identify ligands for biological
targets given that it enables the target to direct the synthesis and amplification of its strongest binder(s) from
the library of interconverting compounds. Since the first report of DCC applied to the discovery of binders for
a protein, this elegant tool has been employed on a range of protein targets at various stages of medicinal-
chemistry projects. A series of suitable, reversible reactions that are biocompatible have been established and
the portfolio of analytical techniques is growing. Despite progress, in most cases, the libraries employed
remain of moderate size. We present here the most recent advances in the field of DCC applied to protein
targets, paying particular attention to the experimental conditions and analytical methods chosen.
Introduction
Dynamic combinatorial chemistry (DCC) allows for the reversible
combination of molecular building blocks via covalent or non-
covalent bonds,1–4 affording dynamic combinatorial libraries
(DCLs) of potentially complex and interchanging products in
an efficient manner. Given that the reaction between the build-
ing blocks is reversible, the product distribution is dictated by
the thermodynamic stability of the compounds formed. A DCL
has the advantage over a classical combinatorial library that it is
responsive to external stimuli such as the addition of a target, which
causes the composition of the library to re-equilibrate upon selec-
tion and binding of the library members with the strongest affinity
for the target.2 Ultimately, this leads to amplification of the best
binders, which can be identified circumventing the need for synth-
esis, purification and characterization of every individual library
member. Protein-templated DCC was used for the first time in the
late 1990’s, leading to the identification of its own inhibitors.5
Protein-templated DCC thus offers an efficient and powerful
approach for the acceleration of the identification and optimization
of novel ligands for biological targets, and therefore holds an
enormous potential for drug discovery (Scheme 1).6–10 In short,
protein-templated DCC combines the synthesis of inhibitors
and screening for affinity for the drug target in a single operation
where the target selects its own inhibitors. We will discuss recent
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applications of DCC for the identification of protein ligands accord-
ing to the type of reversible reaction used over the past decade.
General features of DCC applied to
protein targets
Several reversible reactions have been used in protein-templated
DCC where the target is a protein (Scheme 2).11–18 Most of these
reversible reactions can be carried out in aqueous media, which
makes them biocompatible. The reversible reaction chosen for DCL
formation should equilibrate fast enough under the conditions
where the protein is stable, usually an aqueous medium in a
certain pH and temperature window. In the case of sluggish
reactions, use of a catalyst such as aniline might be required,
which can be used as a nucleophilic catalyst for acylhydrazone
formation.19,20 The reactions should be chemoselective to avoid
cross-reactivity with functional groups of the building blocks or
the target.5,21 DCL formation can be carried out in the presence
(adaptive DCC) or absence (pre-equilibrated DCC) of the target.
The former set-up is certainly preferred as it endows the system
with true adaptability. In the latter case, the protein is added to
the pre-equilibrated DCL, which is necessary for targets that are
unstable under the conditions required for DCL generation.21
To ensure formation of an unbiased DCL, building blocks of
comparable reactivity and energy should be used. If mass
spectrometry (MS) is to be used as an analytical tool, selection
of building blocks should avoid having products or building
blocks of similar or identical molecular weight. Furthermore,
all building blocks and products need to be soluble to preclude
that the DCL is biased by precipitation of some of its members.
Solubility of organic ligands is usually ensured by the use of an
organic co-solvent such as DMSO. The concentration of organic
Scheme 1 Schematic representation of the fundamental concept of
protein-templated DCC.
Scheme 2 Reversible reactions used in protein-templated DCC to generate bioactive compounds.
































































































This journal is©The Royal Society of Chemistry 2015 Chem. Soc. Rev., 2015, 44, 2455--2488 | 2457
co-solvent needs to be chosen such that it maximizes the
solubility of the organic components whilst not affecting the
protein target. A DCL should be ‘‘frozen’’ in the presence of
the target protein for convenient analysis and to ensure its
composition is fixed. There are multiple ways of achieving this:
subsequent irreversible functionalization such as reduction of
the reversible imines to amines,5 pH change from basic to
acidic pH for disulfide exchange or removal or inactivation
of the catalyst.21 It is important to note that the parameters
used for DCL generation will also affect the equilibrium com-
position and amplification factors (e.g., building-block and
target concentration, respectively). Finally, the protocol and
analytical method need to be chosen based on how readily
available the protein is. Saturation-transfer difference (STD)-NMR
spectroscopy, for instance, only works if the ligand is used in
excess, therefore requiring significantly less protein than liquid
chromatography-mass spectrometry (LC-MS).
Reversible covalent bond formation for
protein targets
CQN bond formation
Imine formation. In 1997, the group of Lehn first applied
DCC to a protein target using imine formation/exchange.5 Since
then, imine-based DCC has been used by several groups for
proof-of-concept studies using biological targets.17,22–27 We will
discuss all reports on imine-based protein-templated DCC
since 2008.17,25–27
In 2008, the Rademann group demonstrated that dynamic
ligation screening (DLS), in which a reversibly formed bioactive
ligation product from the DCL competes with a fluorogenic
reporter substrate for a target enzyme, facilitates site-directed
and sensitized detection of low-aﬃnity fragments that are
diﬃcult to detect with normal DCC or conventional fragment-
based drug design (FBDD) approaches.17 By detecting the
fragments using an enzymatic reaction, very small amounts
of protein are suﬃcient, making the screen amenable to a high-
throughput format. SARS coronavirus SARS-CoV Mpro, a cysteine
protease that is crucial for virus replication inside the host cell
and responsible for severe acute respiratory syndrome, was used
as a protein target to pioneer the DLS approach.
To do so, a fluorescence-based assay was developed incorpor-
ating substrate 1.28 A peptide aldehyde inhibitor 2 was chosen as
a directing probe for DLS that mimics the native protease
substrate and addresses the enzyme’s S1, S2 and S3 pockets.
Given that aliphatic aldehydes are less reactive towards imine
formation in aqueous media than aromatic aldehydes, it was
envisaged that the ligation products of the peptide aldehyde 2
and the nucleophiles are only formed when bound to the protein
surface enabling detection by substrate competition. For this
study, a library of 234 amines, thiols and hydrazines were
selected as nucleophiles. Aldehyde 2 was incubated with an
eightfold excess of one nucleophile per well in the presence of
an enzyme. Subsequently, fluorescence was recorded upon addi-
tion of reporter substrate 1.
None of the individual fragments showed inhibition against
the SARS-CoV Mpro, but in the presence of seven nucleophiles
3a–g, aldehyde 2 showed strong inhibitory activity (Table 1). To
validate the specific binding modes of the hits identified, the
most active amine 3a was selected for imine formation with
the aldehyde 2. The corresponding reductive amination pro-
duct 4 was tested and displays an inhibition constant (Ki) of
50.3 mM (Fig. 1). Truncating the amine moiety 3a in compound
4 afforded amine 5, which is inactive (Ki4 500 mM), confirming
the directing effect of peptide aldehyde 2 and validating that
amine 3a binds in the S10 pocket, which was further corroborated
Table 1 Initial velocities (n0) of substrate cleavage in the presence of
SARS-CoV Mpro substrate, aldehyde 2 or 6d and the nucleophiles 3a–j17
Aldehyde Nucleophile n0 (mM min
1)
— — 5.5  0.2
2 2.8  0.1
2 3a 1.0  0.1
2 3b 1.0  0.1
2 3c 1.6  0.1
2 3d 1.9  0.1
2 3e 2.1  0.1
2 3f 2.2  0.1
2 3g 2.2  0.1
6d 3h 2.0  0.05
6d 3i 2.5  0.05
6d 3j 3.7  0.1
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by modeling studies. Further evidence of the specific binding of
amine 3a in the S10 pocket was provided by synthesizing and
testing the aldehyde analogues of amine 3a, which were designed
to interact with the active-site cysteine residue of the protease.
Biochemical evaluation showed that aldehydes 6a–d are active
inhibitors of SARS-CoV Mpro and thus validated the binding mode
Fig. 1 Structures and Ki values of non-peptidic SARS-CoV M
pro inhibitors identified by imine-based dynamic combinatorial chemistry and subsequent
optimization.17
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of the fragments identified by DLS to be indeed in the S10 pocket
of SARS-CoV Mpro.
To obtain a non-peptidic inhibitor of SARS-CoV Mpro target-
ing both the S1 and the S1 0 pockets, a second round of DLS
was carried out in an inverted way using the aldehyde 6d,
which preferentially binds to the S1 0 pocket. A library of 110
amines were selected as nucleophiles. Site-directed DLS
experiments were performed as previously and, three nucleo-
philes 3h–j were identified as active fragments in the presence
of aldehyde 6d (Table 1). The amine 3h appeared to be the
most active fragment, which was then used for the reductive
amination with aldehyde 6d to afford amine 7, which displays
a Ki value of 2.9 mM. This proof-of-concept study shows that
DLS can be used iteratively to first identify a peptidic inhibi-
tor, which was subsequently transformed into a non-peptidic
inhibitor with a low micromolar inhibition constant. DLS
requires low amounts of protein and is compatible with an
HTS format. This approach holds the potential to be readily
extended to other enzyme classes as well as protein–protein
interactions.
In 2009, the groups of Barboiu and Supuran exploited
DCC based on imine interconversion for the identification of
inhibitors of human carbonic anhydrase (hCA II).25 Carbonic
anhydrases are zinc metalloenzymes, which are responsible for
numerous physiological and pathological processes, by catalyz-
ing the hydration of carbondioxide to bicarbonate.29 To demon-
strate the use of reversible imine formation, it was applied for
the DCC-mediated identification of isozyme-specific inhibitors
of the pharmacologically most relevant isoform hCA II. A library
of 20 imines that should have aﬃnity for the hCA II isozyme
were selected. To generate the imine-based DCL, a set of four
aldehydes 8a–d and a ten-fold excess of five amines 9a–e were
employed to ensure full conversion to the corresponding imines
(Scheme 3). Aromatic amines and aldehydes were used given
Scheme 3 (a) Reversible formation of DCLs based on imine formation followed by reduction to the corresponding amines. (b) Initial aldehydes 8a–d
and amine building blocks 9a–e. (c) Inhibitors (8-9) identified from screening experiments with human carbonic anhydrase II.25
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that they form stable Schiff’s bases at pH 6.5, which are able to
interact with different CAs, affording access to potentially effective
inhibitors. The aromatic amines were selected so as to contain a
sulfonamide, a carboxylic and a carboxymethyl group, which are
able to bind zinc strongly, weakly and not at all, respectively.
Various aromatic aldehydes were chosen to explore the
hydrophobic pocket adjacent to the active site of hCA II.
Addition of protein altered the initial equilibrium distribution
of the DCL, which was analyzed in the absence and presence of
protein by HPLC. Having frozen the equilibrium by reducing
the imines to the corresponding amines with NaBH3CN, the
reduced amines were subsequently identified by comparing the
retention time with pure compounds. Some of the imines were
not formed, which might be ascribed to the weak reactivity of
the aromatic amines with electron-withdrawing substituents in
the para-position.30 All possible 20 amines were synthesized and
inhibition constants (Ki) were determined against hCA II (Table 2).
Generally speaking, the DCL screening results correlate with
the inhibition studies. Five amines (8a-9c, 8a-9d, 8a-9e, 8b-9d
and 8d-9e) were amplified in presence of hCA II and three of
them (8a-9c, 8a-9d and 8b-9d) showed amplification factors of
more than 1.4 and very good inhibitory potency confirming the
importance of the sulfonamide moiety of 9c and 9d in combi-
nation with hydrophobic aldehydes 8a and 8b. The poor
correlation observed for the significantly longer ethylamine
8a-9e, which displayed weak inhibition but strong ampli-
fication in the DCL screening, might be due to the strong
aﬃnity of the sulfonamide group for the zinc cation. Amine
8d-9e, which showed strong amplification in the DCL screening
as well as good inhibition of hCA II, seems to constitute a
good balance of unfavorable entropic loss and favorable
enthalpic gain imparted by the longer ethylamine chain of 9e
and the hydrophobic and hydrogen-bonding interactions of
aldehyde 8d, respectively. This study illustrates the power of
imine-based DCC for the identification of enzyme inhibitors
and sets the stage for subsequent optimization of isozyme-
specific inhibitors.
Building on these encouraging results, imine-based DCC
was used to optimize the lead compounds into highly specific
and selective inhibitors of hCA I and hCA II isozymes.26 The
DCLs of six components were generated using two amines 10a
and 10b bearing specific zinc-binding groups and a set of three
hydrophobic aldehydes 11a–c to interact with the hydrophobic
pocket of the enzyme (Scheme 4). The structural variability of
the various substituents on the aromatic ring such as a sulfo-
namide and a sulfonic acid moiety as a strong and relatively
weak zinc-binding group, respectively, were used to generate a
library of diverse affinity for the enzyme. Reaction between
Table 2 Ki values against human carbonic anhydrase II and the relative
HPLC-UV peak areas of the amines identified (reduction of imines) formed
in DCLs25







a Relative peak area was calculated using ratio of HPLC-UV peak area in
presence and absence of protein.
Scheme 4 Generation of imine-based dynamic combinatorial libraries of amines 10a and 10b and aldehydes 11a–c for templating by human carbonic
anhydrase I and II, followed by reduction using NaBH3CN.
26
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amines 10a and 10b and aldehydes 11a–c led to the formation
of six imines 10-11im in equilibrium with the building blocks.
Addition of hCA I and hCA II shifted the equilibrium towards
the strong binders, which were identified just like in the
preceding report after NaBH3CN reduction.
In parallel, all possible six imines (10-11im) and their corres-
ponding amines (10-11) were synthesized separately and tested
for their inhibition (Ki) against hCA I and hCA II. The bio-
chemical results correlate with the DCL-screening results
(Table 3). Only two amines 10a-11c and 10b-11b were amplified
in presence of hCA I. Amine 10a-11c showed a relative peak area
of 4.5 as well as very good inhibition against hCA I, confirming
the strong inhibitory power of the sulfonamide group in
combination with hydrophobic and H-bonding eﬀects of the
aromatic carboxyl group. The presence of 2-fluoro benzaldehyde
(11a) led to a decrease of enzyme inhibition as noticed in
the case of amine 10a-11a. The amine 10a-11b, which showed
similar inhibitory potency to 10a-11c, was not amplified in
presence of hCA I, which might be due to the weak reactivity
of furansulfonic aldehyde 11b. In presence of hCA II, three
amines 10a-11a–c were amplified presumably owing to a better
steric fit into the active site compared to amines 10b-11a–c.
Amine 10a-11a, which showed the same inhibition as 10a-11b
against hCA II, was amplifiedmore than 10a-11b, which could be
due to the presence of fluorine in the aromatic ring. The
presence of a carboxylic acid group in 10a-11c led to ten-fold
weaker inhibitory activity against hCA II. These results demon-
strate the adaptive behavior of the DCL towards two target
isozymes hCA I and hCA II. This concept holds the promise to
be extended to enzyme families with similar active-site features
such as kinases.
In 2013, the group of Guo demonstrated a novel protocol
based on size-exclusion chromatography (SEC) and MS detec-
tion for the direct identification of binders from a DCL through
isolation of ligand–target complexes.27 For the proof-of-principle
study, hen egg-white lysozyme (HEWL) was chosen as the protein
target, which has an important role in immune defense by
degrading and attacking bacterial cell walls. A library of amines
Table 3 Ki values of imine and amine inhibitors of hCA I and II and
amplification factors in presence of hCA I and hCA II26
Inhibitor
Ki (nM) Relative peak area
a
hCA I hCA II hCA I hCA II
10a-11aim 620 7.2
10a-11a 260 6.9 0.6 5.2
10a-11bim 35 4.9
10a-11b 39 7.6 4.4
10a-11cim 65 51
10a-11c 39 57 4.5 3.5
10b-11aim 4100 000 4100 000
10b-11a 4100 000 4100 000
10b-11bim 8960 4100 000
10b-11b 3490 8025 2.8 0.7
10b-11cim 4100 000 4100 000
10b-11c 4100 000 4100 000
a Relative peak area is the experimental peak area in presence of
enzyme in comparison to the reaction in absence of enzyme.
Scheme 5 Generation of pre-equilibrated imine-based dynamic combinatorial libraries of amines 12a–d and aldehydes 13a–h, followed by reduction
using NaBH3CN, incubation with hen egg-white lysozyme (HEWL) and separation of protein–ligand complexes by size-exclusion chromatography (SEC).
27
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were designed based on the imines derived from a set of four
amines 12a–d and eight aldehydes 13a–h (Scheme 5). The pre-
equilibrated DCL was reduced to the corresponding amines
using NaBH3CN and incubated with the protein target HEWL,
before being passed through a suitable SEC column to retain all
non-binders. After denaturation of the eluted protein–ligand
complexes using acetonitrile to release binders, MS analysis
indicated the presence of three amines 12a-13b, 12a-13d and
12a-13f as binders of HEWL, which were confirmed using a
control DCL generated in the absence of the protein.
In a control experiment set up without the reducing agent,
no imines were detected, suggesting that amines rather than
imines are the ligands of HEWL. To validate this hypothesis
and quantify binding aﬃnity towards HEWL, these amines
were synthesized and tested for their eﬀect on the lysis rate
of Micrococcus lysodeikticus.31 The inhibition results (Km values
(Michaelis constants) are reported given that determination
of Ki values was impossible due to incomplete inhibition)
indicate that the binding aﬃnities for HEWL decrease in the
following order 12a-13f 4 12a-13d E 12a-13b (Table 4).
A drawback of this SEC-MS protocols is the limited capacity
of the SEC column. Consequently, the concentration of build-
ing blocks for DCL generation is limited to the micromolar or
even nanomolar range, leading to long equilibration times.
This novel analytical protocol for the analysis of DCLs using
SEC separation of the protein–ligand complexes followed by
denaturation of the complexes and MS analysis has the advan-
tage of circumventing the need for resolution of all library
members by LC, which has been one of the major bottlenecks,
restricting access to significantly larger library sizes. As a result,
this proof-of-concept study sets the stage for application in
early-stage drug discovery programs with protein targets of
therapeutic interest.
Hydrazone formation. Hydrazone chemistry has first been
used by the group of Sanders and Fischer and proved to be
highly suitable for DCL synthesis.32,33 We will discuss a selec-
tion of recent reports on hydrazone-based DCC applied to drug
discovery.16,34,35
In 2003, Congreve and co-workers at Astex Technology
demonstrated for the first time that X-ray crystallography can
be used to detect binders directly from a DCL by exposing
protein crystals to the library.16 The cyclin-dependent kinase 2
(CDK2), which is involved in a number of human cancers, was
used for this proof-of-concept study.36,37 A library of potential
hydrazone inhibitors that would display a variety of functional
groups in the hydrophobic regions of the ATP-binding site was
chosen taking inspiration from the known oxindole inhibitor
series for CDK2. Based on these hydrazones, a range of hydra-
zines 14a–f and isatins 15a–e were selected as the building
blocks for the DCL (Table 5), giving rise to potentially 30
hydrazones. Having established the hydrazone chemistry in
aqueous media, the reactions were performed in presence of
protein crystals.
Soaking experiments with CDK2 crystals and mixtures of the
hydrazine 14e and each of the isatins (15a–e), led to electron
density in the ATP-binding pocket implying that the corresponding
hydrazones had bound to the protein crystal except for one
combination (14e + 15d). Biochemical evaluation of these bound
Table 4 Aﬃnity of binders of hen egg-white lysozyme identified by
dynamic combinatorial chemistry and a size-exclusion chromatography/
mass spectrometry protocol27
Inhibitor Concentration (mM) Km
a (mg mL1)
— — 0.104  0.018
12a-13b 300 0.163  0.022
12a-13d 300 0.162  0.063
12a-13f 300 0.203  0.028
a Km values determined using non-linear regression.
Table 5 Generation of hydrazine-based dynamic combinatorial libraries of hydrazines 14a–f and isatins 15a–e for screening by X-ray crystallography
for binding to cyclin-dependent kinase 2a 16
14  15 14a b 14b R1 = Cl 14c R2 = Cl 14d R3 = Cl 14e R3 = SO2NH2 14f R1 = Cl; R3 = SO2NH2
15a R5 = NO2 10–25 60–95 60–95 30–50 60–95 30–50
15b R5 = Cl 60–95 60–95 60–95 60–95 60–95 30–50
15c R5 = SO3H 10–25 60–95 30–50 10–25 60–95 30–50
15d R7 = CF3 30–50 60–95 60–95 60–95 60–95 30–50
15e R5 = OCF3 30–50 60–95 60–95 60–95 60–95 10–25
a Values indicate the extent to which the reaction occurred in aqueous solution after 2 days at room temperature as measured by percentage purity
using peak area of the product by LC-MS (10–25%, 30–50%, or 60–95% of total peaks excluding solvent front). b R groups = H, unless indicated
otherwise.
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hydrazones showed that all of them are potent inhibitors of CDK2
with IC50 values of 30 nM except for 14e-15d, which was not
observed by protein crystallography and was found to be inactive
against CDK2 (Table 6).
Increasing the level of complexity, this method was used to
analyze the ligands from DCLs. Soaking experiments of two
DCLs containing 14a–d + 15b, 14a–f + 15b and CDK2 crystals
only led to electron density in the ATP-binding pocket for the
latter case corresponding to the potent hydrazone 14e-15b, as
expected. Finally, the full DCL consisting of 14a–f and 15a–e
was exposed to CDK2 crystals, and 14e-15b was again observed
in the ATP-binding pocket, which clearly indicates that X-ray
crystallography is an efficient and powerful technique to detect
binders form DCLs whilst also providing information on the
binding mode. This method also has several advantages over
conventional DCC analytical protocols: it is less time-consuming,
requires small amounts of protein, circumvents the need
for conventional synthesis, purification and analysis of DCL
members and provides the binding mode of the ligands identi-
fied. Despite these unique advantages, this method has not
been followed up on, which is most likely due to the fact that
protein X-ray crystallography requires specific expertise and
infrastructure that is not readily available in an organic chemi-
stry laboratory.
In 2012, the group of Wanner demonstrated an eﬃcient way to
screen DCLs by means of a competitive MS-based binding assay,
combining facile library generation with eﬃcient compound
screening.34 g-Aminobutyric acid (GABA) transporter 1 (GAT1),
the most important subtype of GABA transporters, which is
responsible for neuronal diseases like epilepsy, Parkinson’s
disease and sleeping disorders, was used to demonstrate the
feasibility of this approach.38 A library based on hydrazone
chemistry containing compounds that resemblemGAT1 inhibitors
16–18 were chosen as model compounds for the proof-of-principle
study (Scheme 6a). Based on these hydrazones, a hydrazine 19 and
a set of 36 aldehydes 20 were selected for the generation of DCLs
consisting of 36 hydrazones 19-20 (Scheme 6b). The entire library
was divided in to nine one-dimensional sub-libraries, each
containing four aldehydes and the hydrazine 19 to enable
deconvolution. The hydrazine 19 was used in excess to ensure
a pseudostatic DCL is formed in presence of the target protein
mGAT1. In pseudostatic DCLs, the equilibrium is forced towards
products by using a large excess of the single compound with
fixed structure. The DCLs was then analyzed by the competitive
Table 6 Summary of X-ray crystallography experiments and biochemical-
assay results of hydrazone-based dynamic combinatorial libraries exposed
to crystals of cyclin-dependent kinase 216
Mixture composition Product IC50 (nM)
14e + 15a Yes 30
14e + 15b Yes 30
14e + 15c Yes 30
14e + 15d No Inactive
14e + 15e Yes 30
14a–d + 15b No —
14a–f + 15b Yes (14e-15b) —
14a–f + 15a–e Yes (14e-15b) —
Scheme 6 (a) Structures of GAT1 inhibitors 16–18. (b) Generation of dynamic combinatorial libraries of hydrazones 19-20 using hydrazine 19 and 36
aldehydes 20 for analysis using a competitive MS-based binding assay against the transporter mGAT1.34
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MS-based binding assay, employing the native marker 21. This is
the first report of this highly sensitive assay used for library
screening and involves quantification of a native, i.e., unlabeled
marker, thereby avoiding all the drawbacks associated with
radioisotopes. The assay should be easy to extend to other targets
for which only low concentrations can be reached, such as
transmembrane proteins, provided that the affinity of the marker
is high enough.39
According to deconvolution experiments, the most potent
inhibitors are hydrazones 19-20a and 19-20b followed by
19-20c–e that decrease marker binding to around 10% and
30%, respectively. Interestingly, all five hydrazones are derived
from ortho-substituted benzaldehyde derivatives. Hydrazone
19-20f was also evaluated as it contains an ortho-biaryl moiety,
which decreases marker binding to 65%. To verify the results of
the deconvolution experiments, all hydrazones identified were
synthesized and evaluated for binding affinity. Ki and IC50
values were determined using the MS-based binding assay for
mGAT140 and the [3H]-GABA uptake assay, respectively.41 The
MS-based binding assay not only confirms the high affinity of
inhibitors 19-20a and 19-20b, but also provides the corres-
ponding inhibitory potencies, enabling the ranking of the six
inhibitors according to their inhibitory potency, which is
comparable to the results obtained from the deconvolution
experiments. The most potent inhibitors 19-20a and 19-20b
indeed display the highest potency with pKi values of 6.186 and
6.229, respectively and the medium potent inhibitors 19-20c–f
show pKi values of 5.542, 5.577, 5.445 and 4.479, respectively
(Table 7).
Starting from the two hydrazone-based hits 19-20a and
19-20b with submicromolar activity towards mGAT1, identified
using a competitive MS-based binding assay,34 the former
19-20a was used for DCC-based optimization of its aﬃnity for
mGAT1 by modification of the biphenyl system attached to the
hydrazone linker of both hits (Scheme 7a).35 A library of 36
aldehydes mainly derived from biphenyl-2-carboxyaldehyde
(20a) by varying the substituents on the phenyl ring (22) were
selected for the formation of a hydrazone library 19-22, which
was generated and analyzed as described above using the
hydrazine 19 (Scheme 7b).
In the deconvolution experiments of nine hydrazone libraries,
21 out of the 36 hydrazones showed higher aﬃnity than the
original lead compound 19-20a (pKi = 6.186 0.028), reducing the
MS marker binding to less than 10%. As previously, hydrazones
identified were resynthesized and the binding assay confirmed
their higher aﬃnity compared to the original lead compound
19-20a. Hydrazone 19-22a, containing a 20,40-dichloro biphenyl
moiety emerged as the most potent lead compound with
an aﬃnity in the lower nanomolar range, displaying a pKi =
8.094  0.098, which is 2 log units higher than the original lead
compound 19-20a (Scheme 8). 20,40-Disubstituted biphenyl
rings featuring chloride and to a lesser extent fluoride sub-
stituents appear to be crucial to improve the aﬃnity for mGAT1.
The MS-based binding assay not only confirmed the good
potency of all compounds screened but is also in good agree-
ment with the deconvolution studies.
To develop the hydrazone compounds identified into lead
compounds for drug development, five stable carba-analogues
were synthesized and tested for binding aﬃnity. Like before,
the 20,40-dichloro biphenyl-substituted analogue 23 emerged to
be the most potent mGAT1 binder with a pKi about 1 log unit
lower than 19-22a (Scheme 8). This could be the result of the
decreased polarity of the carba-analogue compared to the
original hydrazone derivative. Taken together, both studies
demonstrate that the competitive MS screening assay of pseudo-
static hydrazone libraries is a powerful and eﬃcient hit-
identification strategy, providing invaluable SAR data, which
can be used for the development of stable lead compounds with
similar aﬃnity to that of the initial hydrazine hits.
Acylhydrazone formation. Acylhydrazone formation, which
was first introduced by Sanders as a powerful reversible system
for abiological DCC,42–44 was used for biological targets by the
group of Lehn.45 We will discuss a selection of recent reports on
acylhydrazone-based protein-templated DCC.11,20,46
Nucleophilic catalysis of acylhydrazone equilibration was
first demonstrated by the group of Greaney in 2010.20 Until
this report, acylhydrazone chemistry was considered to be only
of limited use for protein-templated DCC given the requirement
for acidic pH, which is incompatible with most protein targets.
Table 7 Comparison of marker-binding data (pKi) and mGAT1 activity
(pIC50)
34
Inhibitors R SBa (%) pKi
b pIC50
c
19-20a r5 6.186  0.028 5.308  0.096
19-20b 8.2  0.4 6.229  0.039 5.542  0.107
19-20c 27  1 5.542  0.042 5.186  0.084
19-20d 37  1 5.577  0.037 4.895  0.152
19-20e 24  1 5.445  0.075 4.879
19-20f 65  8 4.479  0.064 4.022
a Specific binding (SB) of 21 determined in deconvolution experiments.
b pKi values were determined by competitive MS-based binding assay
with 21. c pIC50 values were determined by [
3H]-GABA uptake assay
performed in mGAT1-expressing HEK293 cells.34
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This study has shown that in the presence of target protein, the
reversible formation of acylhydrazones can be achieved by using
aniline as a nucleophilic catalyst at relatively less acidic pH. In
the presence of aniline, DCLs are fully reversible and equilibrate
in 6 hours at pH 6.2 instead of 5 days without aniline. The
equilibrium of the DCLs can be switched on and oﬀ by changing
the pH. These DCLs were templated with two isozymes of
glutathione S-transferase (GST), which play an important role
in cell detoxification and are emerging targets for the treatment
of drug resistance in chemotherapy and tropical diseases, and
diﬀerent amplification eﬀects were observed.
DCLs were composed of one aldehyde 24, derived from the
known GST substrate chloro-2,4-dinitrobenzene, and a 2.5-fold
excess of each of the ten hydrazides 25a–j (eight acyl and two
sulfonyl hydrazides) in presence of 10 mM aniline at pH 6.2
(Scheme 9a). The large excess of hydrazides ensures pseudo first-
order behavior and also faster equilibration rates with respect to
the aldehyde. Two recombinant GST isozymes were exposed to the
pre-equilibrated DCLs, and amplification was analyzed. LC-MS
analysis showed that in each of the DCLs a different acylhydra-
zone was amplified: thiophene acylhydrazone 24-25g was ampli-
fied in presence of SjGST and t-butylphenyl hydrazone 24-25c in
presence of hGST (Scheme 9c). Owing to the poor solubility of the
acylhydrazones 24-25g and 24-25c, their accurate IC50 values could
not be determined. To overcome this problem and at the same
time to anchor the compounds at the active site, the DCLs were
regenerated in presence of glutathione (26, GSH)-conjugated
aldehyde 27 and the same ten hydrazides 25a–j (Scheme 9a and b).
As before, similar amplification was observed for both GST
targets: thiophene acylhydrazone 27-25g was selected by SjGST
and t-butylphenyl acylhydrazone 27-25c by hGST (Scheme 9c). To
confirm that the amplification effects are not due to target-
accelerated synthesis, SjGST was added to the pre-equilibrated
DCC, and the same equilibrium distribution was achieved.
Compounds 27-25g and 27-25c were found to have IC50 values
of 22 and 57 mM against SjGST and hGST, respectively.
Building on this initial study, Greaney and co-workers
developed stronger, bivalent acylhydrazone inhibitors of GST
Scheme 7 (a) Structures of original hit 19-20a. (b) Generation of dynamic combinatorial libraries of hydrazones 19-22 using hydrazine 19 and 36
aldehydes 22 for analysis by a competitive MS-based binding assay against the transporter mGAT1.35
Scheme 8 Schematic representation of compounds 19-20a, 19-22a and
23 with their pKi and pIC50 values against the transporter mGAT1.
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isozymes, leading to the most potent inhibitor of the M-class of
this enzyme to date.46 The majority of GST isozymes exist as
homodimers. A bivalent DCC approach has the potential to
lead to more (diverse) compounds using the same number of
building blocks and more potent and selective inhibitors and
represents a novel concept in protein-templated DCC. Potential
drawbacks might be the poor solubility of bisacylhydrazones, a
more challenging analysis as well as less straightforward synth-
esis. A bivalent DCC protocol was designed to selectively target
the GST isozymes. The DCL was constructed using three nitro-
substituted aldehydes 24, 27 and 28, which are derivatives of
chloro-2,4-dinitrobenzene, a weakly binding substrate of all
GSTs and four bivalent hydrazide linkers 29a–d of varying
length and lipophilicity. A DCL of potentially 24 homo- and
hetero-bis-acylhydrazones as well as the mono-acylhydrazones,
excluding E/Z isomers, was generated in presence of 5 mM
aniline at pH 6.2. Four GST isozymes (mGSTM1-1, hGST1-1,
SjGST and mGSTA4-4) were exposed to the pre-equilibrated DCL,
and the best results were obtained for M-class and Sj isozymes,
with the most significant amplification of over 600% by the
M-class for homo-bis-acylhydrazone 27-29c-27 (Scheme 10).
On the one hand, compounds containing the GSH-tagged
aldehyde 27 (27-29c-27, 27-29a-27, 27-29b-27 and 27-29d-27) are
strongly responsive to mGSTM1-1 (Fig. 2). On the other hand,
the DCL is unresponsive to the mGSTA4-4 isozyme. In contrast,
hGSTP-1 appeared to interfere with the DCL equilibrium.
The biochemical data correlate well with the amplification
factors for the mGSTM1-1 isozyme: the inhibitor 27-29c-27
(IC50 = 50 nM) is nearly ten-fold more potent against GST than
the other bis-acylhydrazone products. The inhibition values
Scheme 9 Aniline-catalyzed generation of acylhydrazone-based dynamic combinatorial libraries of (a) aldehydes 24 or 27 and ten hydrazides 25a–j.
(b) Structures of glutathione 26 (GSH) and glutathione-conjugated aldehyde 27. (c) Acylhydrazones amplified in the presence of GST isozymes.20
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for SjGST correlate less well with the amplification factors.
Unfortunately, inhibition data for hGSTP1-1 could not be
correlated with amplification factors, presumably owing to
the lack of a defined equilibration (Table 8). To elucidate the
binding mode of inhibitor 27-29c-27, it was overlaid onto
the crystal structure of hGST M1A-1A (PDB code: 1XWK)
containing the ligand glutathione S-2,4-dinitrobenzene.47
The model indicates that the linker 29c can span the dimer
Scheme 10 Aniline-catalyzed generation of acylhydrazone-based dynamic combinatorial libraries of aldehydes 24, 27, 28 and bishydrazides 29a–d for
templating by GSTs.46
Fig. 2 Amplified GSH-tagged homo-bis-acylhydrazones 27-29-27 in presence of mGSTM1-1 isozyme.46
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interface of hGST M1A-1A without introducing any unfavor-
able interactions.
Taken together, both studies by Greaney and co-workers
show that use of aniline as a nucleophilic catalyst makes
acylhydrazone formation amenable to protein-templated DCC
with a large range of protein targets. This reversible reaction
has numerous advantages such as easily accessible, versatile
building blocks that aﬀord products with the right kinetic and
thermodynamic balance enabling facile and direct analysis
and, in this case, aﬀorded DCLs displaying isozyme selectivity,
leading to the most potent and selective inhibitor of one of the
isozymes reported to date. Furthermore, a bivalent DCC proto-
col should be of particular use for the discovery of inhibitors
targeting large protein surface areas.
In 2014, we demonstrated for the first time that the combi-
nation of de novo structure-based design (SBD) and DCC is a
powerful technique for hit identification and -optimization.11
Whereas SBD is widely used for hit optimization, there are only
a few reports of true de novo SBD. We used endothiapepsin as
the protein target for this proof-of-concept study. Endothiapepsin
belongs to the class of pepsin-like aspartic protease, which play
Table 8 Table of IC50 data of amplified bis-acylhydrazones 27-29-27
against diﬀerent GST isoforms measured by using the CDNB assay46
Acylhydrazone
IC50 (mM)
mGSTM1-1 hGSTP1-1 SjGST mGSTA4-4
27-29c-27 0.050 13.45 0.989 4100
27-29a-27 1.207 126.5 3.471 4100
27-29b-27 0.337 11.81 0.252 4100
27-29d-27 0.413 0.356 1.8 4100
Aldehyde 24 341.7 Z500 265.6 4500
Hydrazide 29c 4500 4500
Scheme 11 Generation of acylhydrazone-based dynamic combinatorial libraries of hydrazides 30a–e and aldehydes 31a–e for analysis by
1H-STD-NMR analysis of binding to the aspartic protease endothiapepsin.11
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a causative role in numerous diseases such as hypertension or
malaria.48 We used two crystal structures of endothiapepsin,
representing two alternative binding modes (with and without a
crystallographically localized water molecule) to design a
library of acylhydrazones, which address the catalytic dyad of
the endothiapepsin either directly via hydrogen bonding or
hydrogen-bonding interactions via the catalytic water molecule.
We used acylhydrazone chemistry as it appeared to be the most
suitable central scaﬀold for eﬃcient anchoring to the active site
through a strong hydrogen-bonding network with the catalytic
dyad. In addition, the pH optimum of endothiapepsin is 4.5,
making it compatible with acylhydrazone chemistry in the
absence of aniline as a catalyst. Retrosynthesis of these designed
acylhydrazones led to five hydrazides 30a–e and five aldehydes
31a–e, which were used to generate the DCLs (Scheme 11). We
used saturation-transfer difference NMR (1H-STD-NMR) spectro-
scopy to identify which component associations are bound to the
enzyme. 1H-STD-NMR spectroscopy enables the direct character-
ization of protein–ligand interactions in solution and is there-
fore a powerful technique for the analysis of DCLs. There is only
one other report of DCLs analyzed by 1H-STD-NMR spectroscopy
by the group of Ramstro¨m, which we will discuss in the section on
hemithioacetal-based DCC.15 To simplify the analysis of the DCL,
we divided the whole library into five sub-libraries, each contain-
ing five hydrazides and one aldehyde, potentially forming five
acylhydrazones and identified the acylhydrazones bound to
the protein by comparing the imine-type and a-carbon proton
signals in the 1H-STD-NMR spectra after addition of endothia-
pepsin to the pre-equilibrated DCLs.
We identified a total of eight acylhydrazones 30-31 from five
sub-libraries (Scheme 11). A fluorescence-based enzyme-activity
assay confirmed that all eight hits from the 1H-STD-NMR analysis
are indeed inhibitors of endothiapepsin with IC50 values in the
range of 13–365 mM. The most potent inhibitors 30c-31e and
30d-31d display IC50 values of 14.5 mM and 12.8 mM respec-
tively, which correlate with the calculated free energies of
binding (Table 9). Subsequent co-crystal structure determina-
tion of 30c-31e (PDB code: 3T7P) and 30d-31d (PDB code: 4KUP)
in complex with endothiapepsin at 1.25 Å and 1.31 Å resolution,
respectively, confirmed the in silico prediction that either direct
or water-mediated hydrogen-bonding interactions with the catalytic
dyad can be achieved (Fig. 3).
Our report shows for the first time that the combination of
DCC and de novo SBD constitutes an eﬃcient and synergistic
approach for hit identification and -optimization of the first
acylhydrazone-based inhibitors of aspartic proteases but could
be extended to potentially any biological target. The binding
Table 9 IC50 values, calculated Ki values, DG of eight acylhydrazones
identified as inhibitors of endothiapepsin11







30a-31a 150  17 71  8 24 28c
30a-31c 365  95 172  45 22 17d
30b-31a 177  13 83  6 23 23c
30c-31a 352  13 166  6 22 26c
30c-31d 206  19 97  9 23 25c
30c-31e 14.5  0.5 7  0.2 30 26d
30d-31d 12.8  0.4 6  0.2 30 32c
30e-31a Insoluble — 23c
a The Gibbs free energy of binding DGEXPT was derived from the experi-
mentally determined IC50 values.
b The calculated Gibbs free energy of
binding DGHYDE was calculated using the HYDE scoring function in the
LeadIT suite. c Result of the docking run without catalytic water molecule
(PDB code: 3PBD). d Result of the docking run with catalytic water mole-
cule (PDB code: 3PI0).
Fig. 3 X-ray crystal structures of endothiapepsin co-crystallized with
ligands: (a) overview of the two molecules of 30c-31e (C: green, water
molecules: red spheres) bound in the active site (PDB code: 3T7P). The
central ligand binds to the catalytic dyad (D35 and D219) via catalytic water
molecule. (b) Overview of two molecules of 30d-31d (C: green, PDB code:
4KUP). The central molecule binds D35 and D219 directly through its
a-amino group.11
Fig. 4 (a) Building blocks 32 and 33a–j used for generation of dynamic
combinatorial libraries using alkene cross metathesis for templating by
bovine carbonic anhydrase II. (b) Structure of 34 used in competitive
fluorescence assay.12
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mode of the most potent hits was validated by protein X-ray
crystallography. The combination of techniques should make
de novo design less risky given that a certain degree of flexibility
can be taken into account during the design stage to account
for potentially flexible regions of the protein target. As a result,
it should become more widely accessible and find application
in a whole range of other classes of drug targets, especially in
the early stages of drug discovery.
C–C bond formation: alkene cross metathesis
Cross metathesis (CM) was first introduced by the group of
Nicolaou, employing a biphasic reaction medium to connect
vancomycin monomers in the presence of dipeptides of the
type D-Ala-D-Ala.49
In 2006, the group of Poulsen first introduced CM to protein-
templated DCC, constituting the first report with a protein target.12
They used an FBDD approach exploiting DCC to identify small-
molecule inhibitors for bovine carbonic anhydrase II (bCA II).
bCA II is an attractive drug target as it is responsible for glaucoma,
epilepsy, gastric ulcers and cancer tumor progression. To facilitate
the proof-of-principle studies, an allylic ester benzene sulfonamide
32 was used as an anchor. The bifunctional building block 32 was
designed so as to contain both an aromatic sulfonamide moiety
and a terminal alkene substituent for recognition of bCA II and
to enable CM, respectively. Ten diverse terminal alkenes 33a–j
(Fig. 4a) were chosen for CM with the anchor building block 32
to explore additional favorable interactions, which might com-
plement the established binding of an aromatic sulfonamide
fragment by bCA II.
A total of ten DCLs were designed, each containing scaﬀold
building block 32 and each individual terminal alkene (33a–j),
resulting in the formation of three-component DCLs, consisting
of homodimers 32-32–33j-33j, etc. individually and heterodimer
32-33a, 32-33b, etc. (Scheme 12). To facilitate the formation of
heterodimers, a ten-fold excess of each terminal alkene (33a–j)
was used with respect to compound 32 in each DCL. The CMwas
performed in presence of 20% Grubbs first-generation catalyst
immobilized on a polystyrene support in dichloroethane as a
solvent. For analysis by ESI-MS and a competitive fluorescence-
based assay with the ligand 5-(dimethylamino)-1-naphthalene-
sulfonamide 34 (dissociation constant Kd (34) = 0.3 mM, Fig. 4b),
samples of the pre-equilibrated DCLs21,45 were diluted with
acetonitrile and water, respectively.
Screening of the DCLs using the competitive binding assay,
revealed that the CM product with the highest aﬃnity is 32-33h
featuring a terminal acetate group, which displaces 34 by 77%.
Weaker binders 32-33i and 32-33j displace 34 by 45% and 37%,
respectively. Next to the heterodimers, only one binding homo-
dimer 32-32 was detected with 88% displacement of 34 (Fig. 4b).
To validate the screening results obtained from crude DCLs,
dimers 32-32 and 32-33h–j were synthesized and tested for
bCA II binding. They were found to display Ki values of 5.1,
4.9, 6.6 and 8.5 nM, respectively (Table 10). These results are in
good agreement with the screening results. This report repre-
sents the first application of both heterogeneous catalysis
and CM as a reversible reaction in protein-templated DCC. The
approach proved to be very efficient in identifying inhibitors of
bCA II and has two main advantages: firstly, the good agreement
between the affinities for the target obtained from the screen of
the DCL without and with prior purification indicates that
synthesis and purification of individual CM products can be
avoided. Secondly, use of a heterogeneous rather than a homo-
geneous catalyst enables straightforward control over the reac-
tion by simple filtration and re-addition of the catalyst. Use of a
water-soluble Grubb’s catalyst should circumvent the require-
ment for the less elegant pre-equilibrated DCC strategy when
using CM as a reversible reaction.50
C–S bond formation
Hemithioacetal formation. In 2010, the group of Ramstro¨m
demonstrated that reversible hemithioacetal formation in
aqueous media can be used for protein-templated DCC.15
b-Galactosidase, a hydrolase that catalyzes the hydrolysis of
O-glycosidic linkages of b-galactosides, was used as a target
protein for the proof-of-concept study. The addition of thiols to
aldehydes leads to the fast and reversible formation of hemi-
thioacetals, which are in equilibrium with the starting materials.
For their proof-of-concept study, Ramstro¨m and co-workers used
a selection of five thiols 35a–e and two aldehydes 36a and 36b based
on the known substrate o-nitrophenyl-b-galactopyranoside (37)
and the inhibitor isopropyl-1-thio-b-D-galactopyranoside (38) of
b-galactosidase (Scheme 13) to construct a DCL of potentially ten
hemithioacetals (20 stereoisomers). Both aldehydes are in equili-
brium with their hydrates 39a and 39b (Scheme 13). 1H-STD-NMR
spectroscopy was used to identify the binders from the DCL,
which we already introduced in the section on acylhydrazone-
based DCC. Given that hemithioacetal formation and dissocia-
tion are fast with respect to the NMR relaxation time at pH =
7.2, required for protein stability, these conditions lead to
virtual DCL formation; only in the presence of enzyme, those
hemithioacetal products that also bind to the target are formed,
leading to a substantial reduction in the signal-to-noise ratio.
1H-STD-NMR analysis of the DCL supported the hypothesis that
only hemithioacetals containing galactose would be selected by
Scheme 12 Generation of pre-equilibrated dynamic combinatorial libraries
using alkene cross metathesis of building blocks 32 and each of 33a–j
individually for templating by bCA II.12
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the protein: the proton signal from compound 35a and both
of the aldehydes 36a and 36b and their hydrates 39a and 39b
are clearly visible. Competition experiment showed that only
the first compound binds specifically to the target. Comparison
of 1H-STD-NMR spectra of the full DCL with subsequent
reference experiments suggested that hemithioacetals 35a-
36a and 35a-36b, containing galactose, are interacting with
b-galactosidase.
To confirm the 1H-STD-NMR results, inhibition assays were
performed for each combination of thiol and aldehyde using the
substrate 37. The hydrolysis of substrate 37 by b-galactosidase to
o-nitrophenol was monitored in presence and absence of each
dynamic system. The hemithioacetals 35a-36a, 35a-36b and thiol
35a were confirmed as the most potent inhibitors, decreasing
the rates of substrate hydrolysis by 12-, 4- and 2-fold, respec-
tively. The combined results of 1H-STD-NMR spectroscopy,
enabling in situ identification of the binders, and the inhibition
assay confirmed the first successful application of hemithio-
acetal formation in protein-templated DCC for the discovery of
b-galactosidase inhibitors. The rapidly equilibrating system
gives rise to virtual DCLs, which enable a rapid and eﬃcient
analysis. Given the labile nature of hemithioacetals, however,








a bCA II binding data using competitive displacement of 34 from bCA
II, Kd (34) = 0.3 mM.
Scheme 13 (a) Generation of hemithioacetal-based virtual dynamic combinatorial libraries of thiols 35a–e and aldehydes 36a and 36b for analysis by
1H-STD-NMR spectroscopy for binding to b-galactosidase. (b) Known substrate 37 and inhibitor 38 of b-galactosidase.15
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transformation into stable analogues is an absolute require-
ment for this reversible system.
Thioether formation. The group of Greaney demonstrated
for the first time in 2006 that the reversible conjugate addition
of thiols to enones can be used in protein-templated DCC.18
This reaction is particularly suitable for protein-templated DCC
given that thioether formation and exchange are fast, freely
reversible, responsive to pH changes and take place in aqueous
media.51 To demonstrate the proof-of-principle, GST was used
as the protein target, which has already been introduced in the
section on acylhydrazone-based DCC. Initially, a biased DCL
was generated to establish equilibration times. Using GSH
(26, endogenous substrate of GSTs) and three GSH analogues
40a–c as the thiol building blocks and ethacrynic acid (EA, 41)
as the enone (Scheme 14). These three GSH analogues were
designed to be weak binders of the GSH-binding site as they
differ from GSH at the g-glutamyl residue, which is crucial for
binding.52 The enone 41 was selected as it is a known inhibitor
of GSTs.
The thiols 26, 40a–c and the enone 41 afforded four
thioethers 41-26 and 41-40a–c, which reached equilibrium in
1 hour and re-equilibrated upon addition of SjGST, collapsing
to only one thioether 41-26 in 10 minutes, indicating that the
enzyme accelerates the conjugate addition. Addition of the
enzyme to the pre-equilibrated DCL, led to the same result
but at a substantially slower rate (6 days), which suggests that
the catalytic effect of SjGST on the conjugate addition does not
affect the equilibrium distribution of the DCL. These experi-
ments indicate that the amplified product 41-26 is a good
binder of SjGST. To confirm that the binding affinity and
amplification correlate with each other, the only amplified
compound 41-26 and a non-amplified compound 41-40c were
synthesized and subjected to the standard GST inhibition
assay.53 Inhibition results showed IC50 values of 0.32 mM and
88 mM for 41-26 and 41-40c, respectively, demonstrating that
the observed amplification is clearly related to binding affinity.
GSTs contain two binding sites, a GSH-binding site, which is
highly conserved and a hydrophobic binding site, called H-site.
To explore the H-site of GSTs, 14 enones 42a–n and 26 as a thiol
building block were selected to construct a DCL (Scheme 15).
The DCL was analyzed in the same way, and three amplified
products 26-42a–c emerged. To investigate the binding affinity
of these amplified products, compounds 26-42a and 26-42c, a
non-amplified product 26-42d and a depleted adduct 26-42e
were synthesized and their IC50 values determined to be
0.61 mM and 1.40 mM for 26-42a and 26-42c, respectively.
Compounds 26-42d and 26-42e show IC50 values of 8.2 mM
and 4.3 mM, which are ten- and seven-fold lower than com-
pound 26-42a (Table 11). These results show that the extent of
amplification correlates with the relative binding affinities of
the DCL members and that the system is capable of differen-
tiating between compounds differing in IC50 value by one order
of magnitude. This study has established a novel reversible
system for protein-templated DCC, namely the conjugate addi-
tion reaction of thiols to enones.
S–S bond formation
Disulfide-bond formation. Reversible disulfide-bond for-
mation was first introduced in DCC by the groups of Still,54
Sanders55 and Lehn21 in the late 1990’s. The first example of
disulfide-based DCC applied to drug discovery was reported by
the group of Lehn in 2000.21 Since then, disulfide-based,
protein-templated DCC has been used by several groups. We
will discuss a selection of recent reports on disulfide-based,
protein-templated DCC.14,56–60
In 2008, the group of Schofield demonstrated that dynamic
combinatorial mass spectroscopy (DCMS) analysis can be used
to analyze DCLs of thiols/disulfides under non-denaturing
conditions.14 DCMS had been introduced by Poulsen for the
identification of bCA II inhibitors.19 BcII metallo-b-lactamase
(BcII MBL) was used as a target for the proof-of-principle study.
The MBL family of enzymes are clinically important as they
catalyze the hydrolysis of almost all clinically used b-lactam
antibiotics, therefore playing an important role in the develop-
ment of resistance against this class of antibiotics.61 Dithiol 43,
which is an analogue of a known inhibitor of the MBL family,62
was selected as a ‘‘support ligand’’. In DCMS, the support
ligand is anchored reversibly to the protein’s active site using
one thiol, leaving the second thiol free for disulfide-bond
Scheme 14 Generation of thioether-based dynamic combinatorial
libraries of thiols 26 and 40a–c and enone 41 for templating by GST.18
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formation with a suitable fragment. In the case of BcII MBL,
the support ligand is anchored to the protein through com-
plexation to the active-site zinc cation using one of the thiols.
Initially, it was shown, using an ESI-MS binding assay,
that compound 43 binds to BcII:Zn2; it is likely that only
one thiol chelates the Zn(II) cation, leaving the other available
for disulfide-bond formation, which confirms that compound
43 is a suitable support ligand.
The first DCL was generated using a set of 19 thiols 44a–s
and the support ligand 43 in presence of BcII (Scheme 16a).
Analysis of the library using DCMS, showed the formation of
BcII:Zn-disulfide complexes after 30 minutes of exposure to air.
Thiophenols 44a–f had reacted with the support ligand 43 to
form disulfide complexes BcII:Zn2-43-44a–f. To replace the
labile disulfide bond of the compounds identified by a stable
linker, a series of cysteine-based analogues were prepared and
tested. Despite not being perfect bioisosteres (the amide linker
used merely mimics the length and stereochemistry), the stable
analogue 45 emerged as the most potent inhibitor with a Ki
value of 740 nM, that is a 170-fold increase in inhibitory
potency with respect to the anchor 43 (Scheme 16b).
As the first DCC revealed that the support-ligand 43 speci-
fically forms disulfide bonds with thiophenols 44a–f to afford
BcII:Zn-disulfide complexes, a second DCL was generated using
a set of thiol-derivatives based on thiophenols 44a–f from the
first DCL and the new thiophenols 45a–m as well as the support
ligand 43 (Fig. 5). DCMS analysis and deconvolution experi-
ments to distinguish between disulfides of identical/similar
mass of the DCL indicated the formation of four disulfide
complexes BcII:Zn2-43-44a–c, BcII:Zn2-43-44d–f, BcII:Zn2-43-45i
and BcII:Zn2-43-45k. To validate the DCMS results, amide analo-
gues 46 and 47 of disulfides 43-45k and 43-45m (the latter was
included as a control given that it was not observed to bind)
respectively, were synthesized and tested for inhibition of BcII.
Despite remaining relatively potent, compounds 46 (Ki = 13.5 mM)
and 47 (Ki = 8.4 mM) did not show any improvement in inhibitory
potency, although MS binding affinity of 46 was significantly
stronger than 47 for BcII:Zn2, which validated the DCMS results.
Overall, this report demonstrates the efficiency of the DCMS
Scheme 15 Generation of thioether-based dynamic combinatorial libraries of GSH (26) and fourteen enones 42a–n for templating by GST.18
Table 11 IC50 values of the amplified (26-42a and 26-42c), non-amplified
(26-42d) as well as depleted adduct (26-42e) upon templating by GST18
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technique for rapid identification of inhibitors, which, unlike
most other analytical techniques enables direct analysis of the
protein–ligand complexes. DCMS provides both the stoichiometry
and binding strength of the protein–ligand interaction and can
be applied even for protein targets for which the substrate is
unknown, a clear advantage over an enzyme-activity assay.
The main drawbacks of this method are that not all proteins
can be used for non-denaturing MS analysis and that not all of
the noncovalent interactions might be translated during the
transition from solution to gas phase in the same manner.63 Up
until now, multiple reports have shown reasonable agreement
between the MS binding results and solution-phase data.14,19,56
Two years later, the established DCMSmethod14 was used by
the same group based on disulfide formation for the ligand
identification of JMJD2E, a member of the subfamily of JMJD2
histone demethylases, which plays a causative role in prostate
cancer, leukemia, squamous cell carcinoma and mental retar-
dation.56 An initial non-denaturing ESI-MS screen of a library
of L- and D-enantiomers of N-oxalyl derivatives of amino acids
was carried out based on the structure of 2-oxoglutarate
(2OG, co-substrate of JMJD2E). The target was found to have
a clear preference for the D-enantiomers. N-oxalyl-D-cysteine
(48), which contains a free thiol group, emerged as a binder
of JMJD2E, making it a suitable support ligand for DCMS
(IC50 = 73 mM). Subsequently, the space available in the
substrate-binding pocket of JMJD2E was explored using DCMS.
In this study, the support ligand 48 is anchored to the active
site through complexation by the N-oxalyl group of the Fe(II)
cation at the active site. This binding mode leaves the thiol
group free for disulfide-bond formation with thiol building
blocks, generating a library of disulfides. The library was then
analyzed using non-denaturing ESI-MS to identify which dis-
ulfide binds to the protein. A set of five thiols 49a–e and
support ligand 48 were used to generate a library of disulfides
in presence of JMJD2E (Fig. 6a). The library was then analyzed
for binding with JMJD2E by non-denaturing ESI-MS, which
revealed the formation of 48-49aJMJD2E and 48-49bJMJD2E
complexes (Fig. 6b), which were further confirmed by deconvo-
lution experiments.
Given that disulfides are not stable under the assay condi-
tions, the corresponding carbon analogues 50 and 51, featuring
a thioether in place of the disulfide linkage, were synthesized
and found to be less potent than the support ligand 48 with
IC50 values of 204 mM and 300 mM, respectively. This discre-
pancy might stem from diﬀerences in the interactions in
solution and the gas phase. Alternatively, thioethers might
simply be a poor bioisostere of disulfide bonds amongst others,
due to diﬀerent conformational preferences of both motifs. The
initial DCMS results indicated that a subpocket of JMJD2E’s
active site is likely to accommodate larger side chains than that
Scheme 16 (a) Generation of disulfide-based dynamic combinatorial libraries of support ligand 43 and thiols 44a–s for templating by BcII. (b) Cysteine-
based stable analogue 45 of disulfide 43-44h.14
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of 48. Consequently, compound 50 was optimized to inhibitor
52 (IC50 = 37.1 mM) by screening a series of N-oxalyl-D-tyrosinyl
derivatives. The predicted binding mode of inhibitor 52 was
validated by solving the co-crystal structure of the complex with
JMJD2A (a member of the JMJD2 subfamily) (PDB code: 2WWJ,
Fig. 7). These results show that DCMS can be applied for the
identification of potent and selective inhibitors of JMJD2E, a
member of the JMJD2 histone demethylase subfamily and
should be easily extended to fragment growing projects invol-
ving other protein targets.
Over the next years, the established DCMS method14 was
again used by the same group to identify small-molecule probes
for the Fe(II)- and 2OG-dependent oxygenase (AlkB), which catalyzes
the hydroxylation of methylated N-methyl-modified DNA/RNA,
ultimately resulting in demethylation using disulfide-based
DCC.57 Small-molecule probes targeting the active site should
be invaluable tools to elucidate the exact molecular role of these
oxygenases. Initially, a non-denaturing ESI-MS screen of a library
of L- and D-enantiomers of N-oxalyl derivatives of amino acids
was carried out showing that AlkB has a clear preference for the
L-enantiomers, which is in contrast to other 2OG-dependent
demethylases. Based on the known, generic inhibitor N-oxalylglycine
(53) and by analogy to the previous study, a suitable support
ligand N-oxalyl-L-cysteine (54) was identified. To explore the
subpocket accessible to the N-oxalyl amino acid series, a library
of 37 thiols 55a–u and 56a–p and the support ligand 54 were
incubated in presence of AlkB and Fe(II) (Fig. 8a). The DCMS
Fig. 5 (a) Thiols used for generation of disulfide-based dynamic combi-
natorial libraries for templating by BcII. (b) Amide analogues 46 and 47 of
disulfides 43-45k,m, respectively based on the second DCMS results.14
Fig. 6 Structures of (a) the support ligand 48 and thiols 49a–e for the generation of disulfide-based dynamic combinatorial libraries for templating by
histone demethylase JMJD2E. (b) Inhibitors identified (48-49) and their stable carbon analogues 50–52.56
Fig. 7 X-ray crystal structure of JMJD2A co-crystallized with inhibitor 52
(color code: protein skeleton: gray; inhibitor skeletons: C: green, N: dark
blue, O: red; Ni(II): violet sphere. (PDB code: 2WWJ).56
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experiments indicated the appearance of two peaks of two
different masses, which could correspond to 16 disulfides.
Given this ambiguous result, a direct consequence of the choice
of building blocks used in the study, ESI-MS analysis of the
16 individual thiols with support ligand 54 was necessary to
identify the bound disulfides unambiguously as 54-55g, 54-55h
and 54-55q (Fig. 8b). Stable carbon analogues 57–59 were
synthesized by replacing the disulfide by a thioether bond
and found to be strong binders of AlkB. These results were
confirmed with inhibition and thermal shift assays, showing
IC50 values of 5.2 mM, 48 mM, 50.4 mM, and melting temperature
shifts of 4.0 1C, 1.8 1C 1.3 1C for 57, 58 and 59, respectively
(Fig. 8b). The binding mode of the inhibitors was then vali-
dated by solving a co-crystal structure of inhibitor 57 and the
optimized derivative 60 (IC50 = 0.5 mM) in complex with AlkB;
both compounds bind to AlkB in an analogous manner to 2OG.
This study illustrates the power of disulfide-based DCC for the
efficient identification of potent and selective inhibitors of the
2OG-dependent nucleic acid-modifying oxygenase AlkB, which
were further optimized based on a co-crystal structure of the
most potent inhibitor identified by DCC. Taken together, the
previous two reports further establish the DCMS method as a
powerful analytical tool for protein-templated DCC.
In 2008, the group of Erlanson pioneered site-directed DCC
based on disulfide exchange, which enables dynamic combi-
natorial screening in a specific pocket of the protein.58 The
kinase Aurora A, which plays an important role in the regula-
tion of mitosis, was used in this study. Taking inspiration from
tethering and tethering with extenders,64,65 which enables
identification of suitable fragments for growing lead com-
pounds through irreversible attachment of the tether to a
cysteine residue, the concept was extended to a fully reversible
system in which the tether is connected to the cysteine residue
via a disulfide bond. First, a cysteine residue was introduced in
proximity of the ATP-binding pocket through site-directed
mutagenesis. The protein was then screened against a library
of 4500 disulfide-containing fragments in presence of a doubly
dynamic extender 61, which is based on diaminopyrimidine
(DAP), known to bind to the ATP-binding site. The extender was
designed to feature two disulfides: one disulfide forms a
reversible covalent bond to the protein through the modified
cysteine residue and the other can react and be extended with
the disulfide-bearing fragments. The resulting protein–extender–
fragment complexes were then analyzed by ESI-MS. To simplify
the screening, several sub-libraries were designed, each of which
contained roughly ten fragments of unique mass; an exemplary
library containing disulfide fragments 62a–j is shown in Fig. 9.
ESI-MS analysis revealed the formation of a complex between
cysteine-modified Aurora A kinase, dynamic extender 61 and the
fragment 62. The hit identified (63) was then converted into a
stable and soluble inhibitor 64 by replacing one disulfide bond
with a flexible alkyl linker and removing the other disulfide from
DAP, displaying an IC50 value of 17 mM. Exchanging the DAP
moiety for a purine or shortening the linker by one carbon atom
aﬀorded more potent inhibitors 65 and 66 with IC50 values of 3.1
and 2.9 mM, respectively. Fragment 62a, which was identified by
DCC, was shown to have an important contribution to the
binding aﬃnity as illustrated by truncating this substituent,
Fig. 8 (a) Initial thiol building blocks 55a–u and 56a–p and the support ligand 54 used for the generation of disulfide-based dynamic combinatorial
libraries for templating by the 2OG-dependent oxygenase AlkB. (b) Disulfides 54-55 identified and their carbon analogues and 57–60.57
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Fig. 9 Generation of disulfide-based dynamic combinatorial libraries of dynamic extender 61 and exemplary disulfides 62a–j for templating by Aurora A
kinase.58
Table 12 IC50 values of the inhibitor of Aurora A kinase identified and its analogues
58
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leading to the inactive compound 67 (Table 12). The X-ray crystal
structure of 66 in complex with Aurora A validated the predicted
binding pose. This study constitutes the first report of site-
directed DCC, enabling growing of a kinase inhibitor beyond
the ATP-binding pocket into the adaptive region. By exploiting
DCC, the requirement for a reactive warhead in ‘‘extended
tethering’’ has been circumvented. The drawback of this
approach is the requirement for a cysteine residue in proximity
to the binding pocket, which needs to be introduced through
site-directed mutagenesis unless it is already present.
In 2009, the group of Ciulli employed disulfide-based DCC
in combination with SBDD to probe the adenosine-binding site
of Mycobacterium tuberculosis pantothenate synthetase, a
potential virulence factor for M. tuberculosis that is required
for pantothenate (vitamin B5) biosynthesis.59 50-Deoxy-5 0-
thioadenosine (68, Scheme 17), derived from the cofactor
ATP, was chosen as an anchor having established its binding
to the ATP-binding site of the target in an 1H-NMR Water-
LOGSY experiment, by isothermal titration calorimetry (ITC)
and by solving an X-ray co-crystal structure in complex with the
target. A set of hydrophobic thiols 69a–d and hydrophilic thiols
69e–h were selected to grow the anchor into the substrate
(pantoate)- and phosphate-binding pockets, respectively
(Scheme 17). In a GSH buffer at pH 8.5, the DCLs generated
using the anchor 68 and the thiols 69a–h were found to
equilibrate within 24 hours.
Analysis by HPLC after acidification and ultrafiltration was
facilitated by selectively monitoring at the absorption maximum
of the anchor 68 (l = 260 nm) so as to only select disulfides
comprising the anchor. The buﬀer was prepared using a reduced
to oxidized GSH ratio of 4 : 1 to bias the DCL towards the thiols
and enable stringent selection of only the strongest disulfide
binders. In the absence of protein target, the dominant species
in the DCL was the disulfide GSH-68. Upon addition of the
protein, a new disulfide 68-69a was amplified as well as the thiol
68 at the expense of the disulfide GSH-68. As predicted by
docking studies, the benzyl group is hosted in the hydrophobic
substrate-binding pocket. This binding hypothesis was con-
firmed by solving the X-ray co-crystal structure of the target in
complex with the hit 68-69a, which suggested that the benzyl
substituent might be decorated with additional functional
groups. A glycerol molecule found in the co-crystal structure
provided additional ideas for the growing and optimization of
the initial hit 68-69a, aﬀording disulfides 70a–b as well as 70c,
the stable thioether derivative of 68b. ITC analysis of all deriva-
tives revealed an approximate two-fold improvement in affinity
of the initial hit 68-69a (Kd = 210 mM) with respect to 68. meta-
Substitution of the benzyl ring with a nitro group in 70a led to a
further optimization of the affinity as reflected in the Kd value of
80 mM. 70b and 70c were found to display a decreased affinity,
which could be ascribed to the flexible glycerol substituent.
Co-crystal structures of 70 and 70c validated the binding hypo-
thesis showing perfect superimposition of the adenosine moieties
with that of 68 and providing insight into the observed differences
in affinity of the derivatives prepared. Taken together, this study
shows the successful identification of a binder of M. tuberculosis
pantothenate synthetase, exploiting an anchor to direct DCC to
the adenosine-binding pocket of the enzyme. Subsequent optimi-
zation based on the co-crystal structure led to a binder with
improved affinity. This fragment-based directed approach should
be applicable to the whole range of adenosine-binding enzymes,
such as kinases.
In 2014, the group of Mahler used DCC based on disulfide
formation for the identification of Trx glutathione reductase
(TGR) inhibitors.60 TGR is an essential enzyme regulating thiol
homeostasis in the flatworm parasite, making it an attractive
anti-infective target. A biased DCL was designed based on two
anchor thiols, the acid 71 and GSH (26), which bind to the
thioredoxin and GSH domains. In addition, four thiol frag-
ments 72a–d were selected for the generation of the DCL at pH
8.8 (Fig. 10), giving rise to potentially 21 disulfides. The DCLs
were then analyzed by LC-MS in negative ion mode. The
reaction took 24 hours to reach equilibrium in the absence of
protein. Protein was added at equilibrium, and the library was
left to re-equilibrate in the absence of oxygen for 24 hours. The
dynamic equilibrium was frozen by addition of trichloroacetic
acid, which also led to denaturation of the protein and con-
comitant release of the bound inhibitors. The library was then
analyzed by LC-MS in negative ion mode and compared to the
LC-MS chromatogram of the blank reaction (without protein).
LC-MS results revealed the appearance of two new peaks corre-
sponding to the diastereomeric mixture of disulfide hetero-
dimers cis/trans-71-72d. The trans-disulfide 71-72d was then
synthesized and its inhibitory potential against TGR was
assayed. trans-71-72d displays an IC50 value of 24.6 mM, which
was optimized by preparing a series of analogues of 71-72d to
afford 73 with an IC50 value 14.0 mM. This study highlights the
use of site-directed DCC for the identification of low-affinity
fragments, which can be used to grow and optimize known
inhibitors and should be directly applicable to other targets.
B–O bond formation: boronate ester formation
Boronate ester formation between boronic acids and diols is
attractive for DCL formation given that it is reversible in
aqueous solution at slightly basic, neutral and slightly acidic
pH depending on the pKa of boronic acid and alcohol, making
it amenable to a large number of targets for protein-templated
DCC.13
In 2011, the group of Claridge pioneered reversible boronate
ester formation for use in protein-templated DCC. The serine
protease a-chymotrypsin (aCT) was chosen as a model enzyme
for this proof-of-principle study.13 11B-NMR and 1H-waterLOGSY
spectroscopy were used to monitor the ternary complexes of
enzyme, boronic acids and sugars (diols in a syn-periplanar
arrangement such as in furanoses aﬀord more stable complexes)
in the DCLs. 11B-NMR spectroscopy has the advantage of not
having any protein background signals and is very eﬃcient for
diﬀerentiating enzyme-bound from free ligands. The quadrupolar
nature of the 11B nucleus (I = 3/2) is used to probe the
hybridization state of the boron atom: broad or sharper peaks
are observed for a 11B nucleus in an sp2-hybridized trigonal
planar or highly symmetrical sp3-hybridized tetrahedral
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environment, respectively.66 Based on known serine-protease
inhibitors, 74a–e (IC50 of 5 mM and 14 mM for 74a and 74b,
respectively) were selected as model boronic acid fragments,
and D-fructose (75a) and L-fructose (75b)67 were selected as the
alcohol fragments for use in DCC (Fig. 11). Given that the pKa of
most boronic acids is around 7–9, the DCC experiments were
conducted at pH 5.8 to ensure the free boronic acid is present
in its sp2-hybridized form.
Initial experiments were carried out using boronic acids 74a
and 74b, 75b and aCT, showing that both 74a and 74b
are equally reactive to boronate ester formation in solution.
11B-NMR spectroscopy was used to monitor the interaction of
boronic acids 74a and 74b with the enzyme aCT in presence
and absence of sugars. Upon addition of 75a, ternary complex
aCT-74a-75a formed preferentially over aCT-74b-75a, which
demonstrates the subtle active-site selectivity (Scheme 18a).
Subsequent experiments using 74a, 75a, 75b and aCT revealed
that 75a readily forms a ternary fructose complex aCT-74a-75a
whereas 30 times more 75b is required to fully form aCT-74a-
75b (Scheme 18b). To demonstrate the pKa dependency of
boronate ester formation, boronic acids 74a and 74c–e were
selected, and cocktails of boronic acids were treated with aCT
in presence of 75a and 75b separately and the formation
of enzyme–boronic acid–sugar complexes was monitored by
11B-NMR spectroscopy at pH 5.8. It was found that upon
addition of aCT to the boronic acid cocktail, only boronic acid
74a formed a complex with aCT. Addition of D-fructose led to
quantitative formation of aCT-74a-75a, whereas addition of 75b
only afforded 50% of aCT-74a-75b (Scheme 18c). These results
suggest that aCT preferentially forms the complex with 74a
out of the cocktail of boronic acids and that 74a and 75a are
Scheme 17 (a) Generation of disulfide-based dynamic combinatorial libraries of thiols 68 and 69a–h for templating by M. tuberculosis pantothenate
synthetase. (b) Hit identified and hit optimization to 70a–c.59
Fig. 10 Thiol building blocks 71 and 72a–d used to generate disulfide-
based dynamic combinatorial libraries for templating by TGR; disulfide
inhibitor 71-72d and its derivative 73.60
Fig. 11 Boronic acids 74a–e and sugars 75a and 75b used to generate
boronate ester-based dynamic combinatorial libraries for templating
by aCT.13
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preferentially bound. 11B-NMR and waterLOGSY spectroscopy
have been used for the first time to analyze DCLs, employing
high or low protein concentrations, respectively. Even though
the latter technique is more sensitive, it is prone to signal
overlap for larger DCLs. This study establishes reversible bor-
onate ester formation as a potentially useful reversible reaction
for protein-templated DCC, extending the palette of reactions
compatible with biomacromolecules, as long as a more suitable
analytical technique is found that enables the analysis of the
labile ternary complexes.
Based on this preliminary proof-of-principle study, the Scho-
field group demonstrated that reversible boronate ester for-
mation in combination with DCMS makes the eﬃcient
identification of protein inhibitors possible.69 The DCMS tech-
nique had previously been used for the analysis of disulfide-
and hydrazone-based DCLS.14,19,57,58 Prolyl hydroxylase domain
isoform 2 (PHD2), a Fe(II)- and 2OG-dependent oxygenase that
controls the human hypoxic response and is used as a target
for the treatment of ischemia-related diseases and anemia,
was used as the protein target. The support ligands 76 or 77
(pKa (76) = 7.4 and pKa (77) = 6.9); the latter was included as a
control and was predicted not to fit into the active site), which
were designed to participate in Fe(II) chelation in the active site
and participate in boronate ester formation, were used as
boronic acid fragments and forty diols (78) in four sets of ten
each were used as alcohol fragments to simplify the analysis for
the formation of DCLs at pH 7.5, making this reaction highly
compatible for protein-templated DCC (Scheme 19a).
The DCLs were synthesized by treating individual ‘‘support
ligands’’ 76 and 77 with forty diols (78) (Scheme 19b). Mild
ESI-MS was use to ensure the correct mass shift of diﬀerent
boronate ester complexes of PHD2Fe(II). DCMS analysis of the
DCLs revealed the formation of boronate esters of only boronic
acid 76 with seven diols (76-78a–g). ESI-MS analysis of boronic
acid 76 with each of the seven individual diols 78a–g validated
the DCMS results.
No boronate ester complex formation was observed with
support ligand 77 with diols 78a–g and PHD2Fe(II). In both
cases, direct binding of some diols to PHD2Fe(II) was observed
in the absence of 76 and 77. This result also implies that the
mass shift observed with 76 represents the boronate ester–
protein complexes rather than the simultaneous binding of 77
and diols.
To validate the DCMS results and ensure that they corre-
spond to the solution-state situation, NMR-based water relaxa-
tion experiments were performed to measure the binding
constants of boronate esters of 76 with PHD2. It was observed
that the apparent aﬃnity of 76 for PHD2 (KD = 24.8 mM)
increased in presence of the diols, which were identified from
DCMS experiments with KD values of 0.6 mM for 76-78a, 1.3 mM
for 76-78b and 3 mM for 76-78c. For further verification of the
use of the labile boronate esters identified, several stable
analogues (79–87) derived from support ligand 76 and diols
78a–g were synthesized, and their binding affinities and IC50
values were determined (Table 13). The stable analogues were
found to be stronger binders than the support ligand 76 but
weaker than the corresponding boronate esters 76–78. To
validate the binding mode of the boronate ester analogues,
compound 87 was crystallized in complex with the catalytic
domain of PHD2 containing Mn(II), mimicking the Fe(II) cation.
The corresponding crystal structure (PDB code: 3HQR) revealed
that 87 complexes the metal cation in a bidentate manner.
Scheme 18 Generation of boronate ester-based dynamic combinatorial libraries for templating by aCT using building blocks (a) 74a, 74b, aCT and 75a;
(b) 74a, aCT, 75a and 75b; (c) 74a, 74c–e, aCT, 75a and 75b.13
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To investigate the efficiency of these compounds in cells,
methyl ester derivative 88 (Scheme 19c) of 85 was tested and
shown to upregulate H1F1a in cells by selectively inhibiting
PHDs but not Factor Inhibiting Hypoxia (FIH). Taken together,
this study demonstrates the potential of boronate ester for-
mation as a novel reversible reaction for protein-templated
DCC. It enabled identification of boronate esters, which were
developed into stable analogues that proved to be selective
inhibitors of the hydroxylase PHD2. Taking advantage of DCMS
as a convenient analytical tool complemented by NMR-based
screening, boronate ester formation should find application to
other protein targets.
Subsequently, the group of the Schofield and the group of
Claridge used reversible boronate ester formation for the
identification of inhibitors of 2OG oxygenases.70 Human 2OG
oxygenases, such as the hypoxia inducible factor (HIF) hydro-
xylases71 are validated drug targets for diseases such as cancer,
inflammation, ischemia and anemia.72 PHD2 and FIH were used
asmodel systems for this study to introduce a competition-based
1H-NMRmethod for the identification of 2OG oxygenase binders
from the DCL. This constitutes as an important alternative to
DCMS, which suﬀers from the potential limitation that not all
non-covalent protein–ligand interactions may be stable during
the solution-to-gas-phase transition. The co-substrate 2OG was
used as a reporter ligand and the endogenous Fe(II) was sub-
stituted by diamagnetic, catalytically inactive Zn(II). This techni-
que depends on the displacement of the reporter ligand 2OG
from the binding pocket upon binding of competitive ligands,
which is monitored via 1H-NMR spectroscopy. An advantage of
this technique is that site-specific binding information as well
as Kd values both for ligands with high and low affinity are
obtained, which is difficult for other ligand-based NMR techni-
ques. Initial screens using known PHD2/2OG inhibitors indi-
cated that the reporter ligand NMR screening is an efficient
means to derive relative strengths of binding at a single inhibitor
concentration. To demonstrate the potential of the NMR-based
method for inhibitor discovery, it was applied to hit validation of
the hits discovered in the previous report.69 The ligand 76, which
binds to the 2OG-binding pocket and is a weak inhibitor of
PHD2, was used as the boronic acid scaffold in combination
with the set of diol hits 78a, 78b, 78d and 78e for the DCC
experiments (Scheme 20). In this proof-of-principle study, the
Scheme 19 (a) Building blocks used to generate boronate ester-based dynamic combinatorial libraries for templating by PHD2. (b) Reversible formation
of boronate esters from boronic acids and diol building blocks. (c) Structure of inhibitor 88.69
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boronic acid scaffold 76 and the diols were subjected to compe-
titive NMR analysis. The boronic acid caused B50% displace-
ment of 2OG, which confirms it as a weak inhibitor of PHD2.
Three-fold higher concentrations of diols were used to ensure
boronate ester formation in each case. Reporter-ligand displace-
ment was not observed for any diol in the absence of boronic
acid, but in presence of boronic acid, B75–85% of 2OG dis-
placement was observed, validating the DCMS screening results
reported earlier.68 Together with a series of control experiments
these results corroborate the hypothesis that boronate esters are
responsible for the displacement of 2OG and thus validate the
potential of this reporter method for hit identification. This
NMR-based method using reporter ligands appears to be a
generic method for the analysis of DCLs using members of the
2OG oxygenase superfamily and should be also applicable to
other enzyme families. It has the advantage of using substoichio-
metric amounts of unlabeled protein and provides information
on the binding mode as well as the KD values.
Metal–ligand coordination
Fe  N coordination. In 2013, the group of de Mendoza
demonstrated for the first time that multicomponent exchan-
ging DCLs of Fe(II)–bipyridine (Fe(II)–bipy) complexes can
be used for carbohydrate–protein recognition studies.73 Pre-
viously, a prototype DCL was reported by Sasaki consisting of
four stereoisomers of a homoleptic Fe(II)–bipy complex for
lectin (carbohydrate-binding protein) recognition.74 The equili-
brium was shifted towards a specific stereoisomer in presence
of the target lectin. Similarly, intermolecular exchange of two
Co(II)–bipy complexes was reported by the group of Lehn but
not for protein recognition.75 Despite of these preliminary
studies, this strategy had never been applied to multicompo-
nent DCLs for protein recognition.
The lectin concanavalin A (ConA) was used as the target for
the proof-of-principle study. To establish the reversibility of the
Fe(II)–bipy complexes, a small DCL was generated by mixing
two homoleptic Fe(II)–bipy complexes 89a and 89b in aceto-
nitrile. Due to ligand exchange, a library of four complexes 89a–d
was formed and reached equilibrium after five days (Scheme 21a).
The library was analyzed using LC-MS.
Building on this successful result, a bigger library of ten
members (89e–n) was constructed by mixing three homoleptic
Fe(II)–bipy complexes 89e (Fe-MMM), 89f (Fe-GGG) and 89g
(Fe-FFF) (Scheme 21b). Ligands of these Fe(II)–bipy complexes
consisted of bipy ligands connected to different sugar moieties
such as D-mannoside (M), D-galactoside (G) and L-fucoside (F)
via a flexible spacer. These sugars were chosen based on their
reported binding affinities towards ConA (M 4 F, G). A DCL
was set up at low temperature (5 1C) to avoid dissociation of
Fe(II)–bipy complexes and required 14 days to reach equili-
brium. Given that the masses of galactose and mannose are
identical, the retention time (Fe-GGG o Fe-MMM o Fe-FFF)
was considered alongside the MS result for unequivocal peak
assignment. Subsequently, a similar library was set up by
mixing three homoleptic Fe(II)–bipy complexes 89e (Fe-MMM),
89f (Fe-GGG) and 89g (Fe-FFF) in presence of sepharose-bound
ConA and allowed to equilibrate for 14 days. The bound ligands
were separated by filtration and re-suspended in aqueous HCl
to release the bound complexes from the protein surface.21 LC-
MS analysis of this fraction showed the full mannoside complex
89e (Fe-MMM) as the most abundant species with seven-fold
amplification in comparison to the library without protein
along with other two mannoside-rich complexes 89h (Fe-GMM)
and 89i (Fe-MMF). Taken together, these results show that DCC
Table 13 Binding constants (KD) and IC50 values of the selected inhibitors
of PHD269
Compound R X KD (mM) IC50 (mM)
76 H 24.8 126
79 H H — 41000
80 H 9.5 4500
81 H 7.0 4500
82 H 1.6 107
83 H 8.7 4100
84 H OH 3.5 409
85 OH 0.5 0.017
86 OH 0.8 0.013
87 OH 0.9 0.004
Scheme 20 Generation of boronate ester-based dynamic combinatorial
libraries using building blocks 76, 78a, 78b, 78d and 78e for analysis by a
competition-based NMR method of binding to PHD2.70
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Scheme 21 (a) Generation of Fe(II)–bipy complex-based dynamic combinatorial libraries of a complexes 89a and 89b. (b) Complexes 89e–g for
templating by lectin concanavalin A.73
Fig. 12 Generation of oxorhenium-complex-based dynamic combinatorial libraries of proline analogues 90a–p and thiols 91a–p for templating by
human peptidyl-prolyl isomerase hCyp-18.76
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based on metal–ligand complexation can be used for protein–
ligand recognition and can potentially be extended to drug
discovery of any target, whilst taking advantage of multivalency
to improve binding affinity. The main limitations of this method
are the unclear spatial arrangement of the ligands in hetero-
geneous complexes, highly reversible nature and potential toxi-
city issues of the metal complexes. Using a target bound to a
solid support has the advantage of reducing the analytical
challenge simply by removing all unbound library members
before analysis.
Re  S coordination. In 2008, the group of Dugave demon-
strated a simple and straightforward method for the identifi-
cation of ligands for a protein target using reversible
oxorhenium-complex formation.76 Cyclophilin hCyp-18, which
is an important human peptidyl-prolyl isomerase, was used for
the proof-of-principle study as the protein target. For this study,
16 building blocks of type A (90a–p, Fig. 12) that are linked to
the recurrent N(CH2–CH2)2 motif and 16 building blocks of type
B (91a–p, Fig. 12) that feature a thiol moiety were used for the
formation of a library of oxorhenium complexes after reduction
of the disulfide by chelation of a ReO3+ core (oxorhenium
gluconate was used to ensure solubility in the aqueous buffer
required by the protein target). The S1–S10 pocket of hCyp-18
was expected to bind building block 90a–p, which contains a
proline analogue, whereas the S2–S30 subsite was expected to
recognize the building block 91a–p, which contains an amino
acyl-( p-nitroanilide) surrogate. The libraries were analyzed
using LC-MS (ESI-MS in positive mode), and the expected
rhenium complexes were identified by analyzing the character-
istic 32–34S/185–187Re isotope patterns.
To validate the strategy, a small library of 16 oxorhenium
complexes was synthesized by reduction and incubation of dis-
ulfides 90a–d and thiols 91a and 91i (Scheme 22a). As expected, all
16 complexes were formed as amixture of diastereoisomers. Upon
addition of hCyp-18, yields of these complexes barely varied except
for 90d-91i, which was amplified after addition of the target
hCyp-18 (‘‘cylcophilin-enhancing effect’’). These complexes bind
to hCyp-18 in the submillimolar range except for the complex
90d-91i, which was found to be a strong binder with a Kd value of
11  2 mM (IC50 = 12 mM). Interestingly, upon addition of GSH,
all complexes readily dissociated except for 90d-91i, which was
stable even at high GSH concentrations. This effect was called
‘‘cyclophilin-protecting effect’’ and results from a protective effect
Scheme 22 (a) Generation of oxorhenium-complex-based dynamic combinatorial libraries of disulfides 90a–d and diols 91a and 91i for templating by
human peptidyl-prolyl isomerase hCyp-18; (b) DCLs containing disulfides 90e–p and each of 16 thiols 91a–p.76
Table 14 Apparent Kd and IC50 values of binders identified
76
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of the protein target against thiol exchange of interacting complexes.
The positive ‘‘cylcophilin-enhancing effect’’ and ‘‘cyclophilin-
protecting effect’’ from GSH strongly suggest that the oxorhenium
complex 90d-91i specifically interacts with the protein hCyp-18 as
also indicated by a competition experiment with the known
inhibitor cyclosporine.
After successful application of the reversible oxorhenium
complex formation using a small library of fragments for ligand
identification of hCyp-18, a larger library was investigated in
the same manner using modules 90e–p and modules 91a–p
(Scheme 22b), affording 192 possible complexes. To facilitate
analysis, the whole library was divided into 16 sub-libraries,
each containing twelve disulfide building blocks 90e–p and one
of the 16 thiols 91a–p. LC-MS analysis of these DCLs showed
that only complexes 90e-91b, 90i-91b and 90p-91n displayed
higher resistance to GSH in the presence of hCyp-18, which
were selected as potential cyclophilin inhibitors. Subsequently,
these complexes were synthesized as a mixture of diastereo-
isomers and tested for binding affinity, displaying Kd values of
0.3–2 mM (Table 14). Reversible oxorhenium coordination pro-
vides an efficient and straightforward access to protein ligands,
affording compounds with submicromolar affinity for hCyp-18.
Drawbacks include the sensitivity of the complexes to endo-
genous thiols such as GSH. Nevertheless, this strategy provides
access to the rapid identification of non-peptidic inhibitors,
which should be particularly useful to target surface proteins
and replacement of the ReO3+ by a TcO3+ core would turn them
into molecular imaging agents.
Conclusions
Over the past 15 years, DCC has rapidly evolved and our
understanding of the underlying concepts has grown tremen-
dously. DCC is an exquisite tool that enables the eﬃcient
development of novel compounds with potentially interesting
biological activities. Given that it combines in situ synthesis of
covalently or non-covalently connected building blocks and
screening of the potential binders against the target, it holds
the potential of dramatically accelerating the drug-discovery
process. Structural diversity can be readily accessed and
screened. A variety of protein targets have been used, illustrat-
ing that a suitable reversible reaction and analytical method
can be selected to enable DCC (Table 15). Mainly covalent
reversible reactions but also non-covalent reversible reactions
have been used to generate libraries of potential binders at
various stages in a medicinal-chemistry or chemical-biology
project: it has been used in FBDD to screen for low aﬃnity
fragments, hit identification, validation as well as optimization
and elucidation of the role or mechanism of a protein of
interest. The potential of DCC is certainly largest in the early
stages of the drug-discovery process. For targets featuring ill-
defined pockets that cannot be addressed easily by SBDD, DCC
should represent a particularly elegant alternative.
There are some limitations of protein-templated DCC that
will have to be tackled, namely the use of larger and more
complex libraries. Other drawbacks can include long equili-
bration times that are not tolerated by particularly unstable
proteins or the pronounced dynamic nature of several reversible
reactions, causing the potential inhibitors to hydrolyze or decom-
pose, leading to potentially toxic compounds and hampering
straightforward analysis. As a result, protein-templated DCC
should be followed by bioisosteric transformation of unstable
inhibitors to stable analogues without a concomitant loss in
activity.
Most examples reported so far use libraries of small or
moderate size and relatively well-established protein targets,
which may well be due to the limits of the analytical techni-
ques. On the other hand, some elegant tricks have been
developed that should enable use of DCC also with precious
protein targets and larger libraries. The time has come for
protein-templated DCC to fulfil its full potential and truly
revolutionize the drug-discovery process.
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